* The list is adopted from the table of interaction in medis (Medikamenten-Informations-Systems) for clarithromycin and clarithromycin package insert. ¶ The interaction is not addressed in medis but in clarithromycin product information. 1 "Cholestrol-Synthese-Hemmer", albeit excluding fluvastatin and rosuvastatin which are not dependent on CYP3A metabolism. 4 fentanyl and its derivatives 5 H1-antihistamines (second-generation) 6 Phosphodiesterase-5 inhibitors 7 Ivacaftor is a sensitive CYP3A substrate. Co-administration with ketoconazole, a strong CYP3A inhibitor, significantly increased ivacaftor exposure [measured as area under the curve (AUC)] by 8.5-fold (Ivacaftor product information). AUC increase by clarithromycin is predicted 4.35 fold by using method presented by Hisaka 2009. 8 Co-administration of brentuximab vedotin, primarily metabolized by CYP3A, with ketoconazole increased exposure to brentuximab vedotin by approximately 34% (ADCETRIS TM (brentuximab vedotin) product information). AUC increase by clarithromycin is predicted 1.28 fold by using method presented by Hisaka 2009. 9 Co-administration of single doses of the P-gp inhibitor cyclosporine A and DIFICLIR in healthy volunteers, resulted in a 4-and 2-fold increase in fidaxomicin Cmax and AUC, respectively and in a 9.5 and 4-fold increase in Cmax and AUC, respectively, of the main active metabolite OP-1118. As the clinical relevance of this increase in exposure is unclear, co-administration of potent inhibitors of P-gp, such as cyclosporine, ketoconazole, erythromycin, clarithromycin, verapamil, dronedarone and amiodarone are not recommended (DIFICLIR®(fidaxomicin tablet) product information). 10 The Cmax and AUC of ruxolitinib increased 33% and 91%, respectively, with Jakafi administration (10 mg single dose) following ketoconazole 200 mg twice daily for four days, compared to receiving ruxolitinib alone in healthy subjects (JAKAFI™ (ruxolitinib) product information). AUC increase by clarithromycin is predicted 1.69 fold by using method presented by Hisaka 2009. 
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1 Bosentan is an endothelin receptor antagonist. Coadministration of bosentan decreased the plasma concentrations of simvastatin (a CYP3A substrate), and its active β-hydroxy acid metabolite, by approximately 50%. The plasma concentrations of bosentan were not affected (TRACLEER® (bosentan) product information).
2 Cholestyramine is a strongly basic "ion-exchange resin". An in vivo animal experiment demonstrated a significant reduction (about 50% with AUC) in the concentration of active hydroxy acid form of simvastatin in plasma following the co-administration of simvastatin (500 mg/kg p.o.) and cholestyramine (600 mg/kg p.o.), compared with the administration of simvastatin alone (Nakai 1996 * The list is adopted from the table of interaction in medis (Medikamenten-Informations-Systems) for pravastatin and pravastatin package insert. 1 Cimetidine (300 mg QID for 3 days) plus pravastatin (20 mg single dose) increased area under the serum concentration-time curve (AUC) of pravastatin by 30% (PRAVACHOL®(rosuvastatin calcium) product information). 2 Verapamil (Verapamil IR 120 mg for 1 day and Verapamil ER 480 mg for 3 days) plus pravastatin (40 mg single dose) increased area under the serum concentration-time curve (AUC) of pravastatin by 31% (PRAVACHOL®(rosuvastatin calcium) product information). 1 Results from in vitro and in vivo studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4). Concomitant administration of itraconazole (an inhibitor of CYP3A4) and rosuvastatin resulted in a 28% increase in AUC of rosuvastatin. This small increase is not considered clinically significant. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected (Summary of Product Characteristics (SmPC) presented by EMEA for rosuvastatin). 2 Dronedarone (400 mg BID) plus rosuvastatin (10 mg) increased area under the serum concentration-time curve (AUC) of rosuvastatin by 1.4 fold (CRESTOR®(rosuvastatin calcium) product information). 3 Ezetimibe (10 mg QD, 14 days) plus rosuvastatin (10 mg QD, 14 days) increased area under the serum concentration-time curve (AUC) of rosuvastatin by 1.2 fold (CRESTOR®(rosuvastatin calcium) product information).
Antagonistic Interaction with Pravastatin
